Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The co-encapsulation of OXA and IO-OA was achieved in two types of polymeric carriers, namely, PLGA and poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) by double emulsion. PLGA_IO-OA_OXA and PEGylated PLGA_IO-OA_OXA nanoparticles displayed a comparable mean diameter of 207 ± 70 nm and 185 ± 119 nm, respectively. The concentration of the released OXA from the PEGylated PLGA_IO-OA_OXA increased very rapidly, reaching ~100% release after only 2 h, while the PLGA_IO-OA_OXA displayed a slower and sustained drug release. Therefore, for a controlled OXA release, non-PEGylated PLGA nanoparticles were more convenient. Interestingly, preservation of the superparamagnetic behavior of the IO-OA, without magnetic hysteresis all along the dissolution process, was observed. The non-PEGylated nanoparticles (PLGA_OXA, PLGA_IO-OA_OXA) were selected for the anti-CD133 Ab conjugation. The affinity of Ab-coated nanoparticles for CD133-positive cells was examined using fluorescence microscopy in CaCo-2 cells, which was followed by a viability assay.

Faculty of Chemical Engineering University of Chemistry and Technology Prague 166 28 Prague Czech Republic

Faculty of Food and Biochemical Technology University of Chemistry and Technology Prague 166 28 Prague Czech Republic

Faculty of Technology Tomas Bata University 760 01 Zlín Czech Republic

See more in PubMed

Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI

Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; Lyon, France: 2020.

Bishehsari F., Mahdavinia M., Vacca M., Malekzadeh R., Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J. Gastroenterol. 2014;20:6055–6072. doi: 10.3748/wjg.v20.i20.6055. PubMed DOI PMC

Arnold M., Abnet C.C., Neale R.E., Vignat J., Giovannucci E.L., McGlynn K.A., Bray F. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020;159:335–349. doi: 10.1053/j.gastro.2020.02.068. PubMed DOI PMC

Heidelberger C., Chaudhuri N.K., Danneberg P., Mooren D., Griesbach L., Duschinsky R., Schnitzer R.J., Pleven E., Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–666. doi: 10.1038/179663a0. PubMed DOI

Danenberg P.V. Thymidylate synthetase—A target enzyme in cancer chemotherapy. Biochim. Biophys. Acta. 1977;473:73–92. doi: 10.1016/0304-419X(77)90001-4. PubMed DOI

Poon M.A., O’Connell M.J., Moertel C.G., Wieand H.S., Cullinan S.A., Everson L.K., Krook J.E., Mailliard J.A., Laurie J.A., Tschetter L.K., et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. 1989;7:1407–1418. doi: 10.1200/JCO.1989.7.10.1407. PubMed DOI

Mini E., Trave F., Rustum Y.M., Bertino J.R. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol. Ther. 1990;47:1–19. doi: 10.1016/0163-7258(90)90042-Z. PubMed DOI

Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl. J. Med. 2000;343:905–914. doi: 10.1056/NEJM200009283431302. PubMed DOI

Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Pitot H.C., Alberts S.R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004;22:23–30. doi: 10.1200/JCO.2004.09.046. PubMed DOI

Lee R.M., Cardona K., Russell M.C. Historical perspective: Two decades of progress in treating metastatic colorectal cancer. J. Surg. Oncol. 2019;119:549–563. doi: 10.1002/jso.25431. PubMed DOI

Gustavsson B., Carlsson G., Machover D., Petrelli N., Roth A., Schmoll H.J., Tveit K.M., Gibson F. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin. Colorectal Cancer. 2015;14:1–10. doi: 10.1016/j.clcc.2014.11.002. PubMed DOI

Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Cote J.F., Tomasic G., Penna C., Ducreux M., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995. doi: 10.1158/0008-5472.CAN-06-0191. PubMed DOI

Matos A.I., Carreira B., Peres C., Moura L.I.F., Conniot J., Fourniols T., Scomparin A., Martinez-Barriocanal A., Arango D., Conde J.P., et al. Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. J. Control. Release. 2019;307:108–138. doi: 10.1016/j.jconrel.2019.06.017. PubMed DOI

Yassin A.E., Anwer M.K., Mowafy H.A., El-Bagory I.M., Bayomi M.A., Alsarra I.A. Optimization of 5-flurouracil solid-lipid nanoparticles: A preliminary study to treat colon cancer. Int. J. Med. Sci. 2010;7:398–408. doi: 10.7150/ijms.7.398. PubMed DOI PMC

Mattos A.C., Altmeyer C., Tominaga T.T., Khalil N.M., Mainardes R.M. Polymeric nanoparticles for oral delivery of 5-fluorouracil: Formulation optimization, cytotoxicity assay and pre-clinical pharmacokinetics study. Eur. J. Pharm. Sci. 2016;84:83–91. doi: 10.1016/j.ejps.2016.01.012. PubMed DOI

Feng S.T., Li J., Luo Y., Yin T., Cai H., Wang Y., Dong Z., Shuai X., Li Z.P. pH-sensitive nanomicelles for controlled and efficient drug delivery to human colorectal carcinoma LoVo cells. PLoS ONE. 2014;9:e100732. doi: 10.1371/journal.pone.0100732. PubMed DOI PMC

Hosseinzadeh H., Atyabi F., Varnamkhasti B.S., Hosseinzadeh R., Ostad S.N., Ghahremani M.H., Dinarvand R. SN38 conjugated hyaluronic acid gold nanoparticles as a novel system against metastatic colon cancer cells. Int. J. Pharm. 2017;526:339–352. doi: 10.1016/j.ijpharm.2017.04.060. PubMed DOI

Kuo C.Y., Liu T.Y., Chan T.Y., Tsai S.C., Hardiansyah A., Huang L.Y., Yang M.C., Lu R.H., Jiang J.K., Yang C.Y., et al. Magnetically triggered nanovehicles for controlled drug release as a colorectal cancer therapy. Colloids Surf. B: Biointerfaces. 2016;140:567–573. doi: 10.1016/j.colsurfb.2015.11.008. PubMed DOI

Di Francesco A.M., Ruggiero A., Riccardi R. Cellular and molecular aspects of drugs of the future: Oxaliplatin. Cell. Mol. Life Sci. 2002;59:1914–1927. doi: 10.1007/PL00012514. PubMed DOI PMC

Kim G.P., Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin. Drug Metab. Toxicol. 2007;3:281–294. doi: 10.1517/17425255.3.2.281. PubMed DOI

Pietrangeli A., Leandri M., Terzoli E., Jandolo B., Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur. Neurol. 2006;56:13–16. doi: 10.1159/000094376. PubMed DOI

Krishnan A.V., Goldstein D., Friedlander M., Kiernan M.C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32:51–60. doi: 10.1002/mus.20340. PubMed DOI

Beijers A.J., Mols F., Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support. Care Cancer. 2014;22:1999–2007. doi: 10.1007/s00520-014-2242-z. PubMed DOI

Makadia H.K., Siegel S.J. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers. 2011;3:1377–1397. doi: 10.3390/polym3031377. PubMed DOI PMC

Sinha V.R., Bansal K., Kaushik R., Kumria R., Trehan A. Poly-ϵ-caprolactone microspheres and nanospheres: An overview. Int. J. Pharm. 2004;278:1–23. doi: 10.1016/j.ijpharm.2004.01.044. PubMed DOI

Llorens E., Pérez-Madrigal M.M., Armelin E., del Valle L.J., Puiggalí J., Alemán C. Hybrid nanofibers from biodegradable polylactide and polythiophene for scaffolds. RSC Adv. 2014;4:15245–15255. doi: 10.1039/c3ra42829j. DOI

Kapoor D.N., Bhatia A., Kaur R., Sharma R., Kaur G., Dhawan S. PLGA: A unique polymer for drug delivery. Ther. Deliv. 2015;6:41–58. doi: 10.4155/tde.14.91. PubMed DOI

D’Avila Carvalho Erbetta C. Synthesis and Characterization of Poly(D,L-Lactide-co-Glycolide) Copolymer. J. Biomater. Nanobiotechnology. 2012;3:208–225. doi: 10.4236/jbnb.2012.32027. DOI

Hermanson G.T. Chapter 18—PEGylation and Synthetic Polymer Modification. In: Hermanson G.T., editor. Bioconjugate Techniques. 3rd ed. Academic Press; Boston, MA, USA: 2013. pp. 787–838.

Kocbek P., Obermajer N., Cegnar M., Kos J., Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control. Release. 2007;120:18–26. doi: 10.1016/j.jconrel.2007.03.012. PubMed DOI

Vij N., Min T., Marasigan R., Belcher C.N., Mazur S., Ding H., Yong K.T., Roy I. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J. Nanobiotechnology. 2010;8:22. doi: 10.1186/1477-3155-8-22. PubMed DOI PMC

Zumaya A.L.V., Ulbrich P., Vilčáková J., Dendisová M., Fulem M., Šoóš M., Hassouna F. Comparison between two multicomponent drug delivery systems based on PEGylated-poly (l-lactide-co-glycolide) and superparamagnetic nanoparticles: Nanoparticulate versus nanocluster systems. J. Drug Deliv. Sci. Technol. 2021;64:102643. doi: 10.1016/j.jddst.2021.102643. DOI

Zumaya A.L.V., Martynek D., Bautkinová T., Šoóš M., Ulbrich P., Raquez J.-M., Dendisová M., Merna J., Vilčáková J., Kopecký D., et al. Self-assembly of poly(L-lactide-co-glycolide) and magnetic nanoparticles into nanoclusters for controlled drug delivery. Eur. Polym. J. 2020;133:109795. doi: 10.1016/j.eurpolymj.2020.109795. DOI

Jia Y., Yuan M., Yuan H., Huang X., Sui X., Cui X., Tang F., Peng J., Chen J., Lu S., et al. Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int. J. Nanomed. 2012;7:1697–1708. doi: 10.2147/IJN.S28629. PubMed DOI PMC

Laurent S., Dutz S., Hafeli U.O., Mahmoudi M. Magnetic fluid hyperthermia: Focus on superparamagnetic iron oxide nanoparticles. Adv. Colloid Interface Sci. 2011;166:8–23. doi: 10.1016/j.cis.2011.04.003. PubMed DOI

Soares P.I., Alves A.M., Pereira L.C., Coutinho J.T., Ferreira I.M., Novo C.M., Borges J.P. Effects of surfactants on the magnetic properties of iron oxide colloids. J. Colloid Interface Sci. 2014;419:46–51. doi: 10.1016/j.jcis.2013.12.045. PubMed DOI

Soares P.I.P., Laia C.A.T., Carvalho A., Pereira L.C.J., Coutinho J.T., Ferreira I.M.M., Novo C.M.M., Borges J.P. Iron oxide nanoparticles stabilized with a bilayer of oleic acid for magnetic hyperthermia and MRI applications. Appl. Surf. Sci. 2016;383:240–247. doi: 10.1016/j.apsusc.2016.04.181. DOI

Patel J., Amrutiya J., Bhatt P., Javia A., Jain M., Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J. Microencapsul. 2018;35:204–217. doi: 10.1080/02652048.2018.1453560. PubMed DOI

Singh S., Kumar N.K., Dwiwedi P., Charan J., Kaur R., Sidhu P., Chugh V.K. Monoclonal Antibodies: A Review. Curr. Clin. Pharmacol. 2018;13:85–99. doi: 10.2174/1574884712666170809124728. PubMed DOI

Belov L., Zhou J., Christopherson R.I. Cell surface markers in colorectal cancer prognosis. Int. J. Mol. Sci. 2010;12:78–113. doi: 10.3390/ijms12010078. PubMed DOI PMC

Moreno D., de Ilarduya C.T., Bandres E., Bunuales M., Azcona M., Garcia-Foncillas J., Garrido M.J. Characterization of cisplatin cytotoxicity delivered from PLGA-systems. Eur. J. Pharm. Biopharm. 2008;68:503–512. doi: 10.1016/j.ejpb.2007.08.006. PubMed DOI

Carter T., Mulholland P., Chester K. Antibody-targeted nanoparticles for cancer treatment. Immunotherapy. 2016;8:941–958. doi: 10.2217/imt.16.11. PubMed DOI

Veiseh O., Gunn J.W., Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv. Drug Del. Rev. 2010;62:284–304. doi: 10.1016/j.addr.2009.11.002. PubMed DOI PMC

Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., Levy-Nissenbaum E., Radovic-Moreno A.F., Langer R., Farokhzad O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28:869–876. doi: 10.1016/j.biomaterials.2006.09.047. PubMed DOI PMC

Li Y.P., Pei Y.Y., Zhang X.Y., Gu Z.H., Zhou Z.H., Yuan W.F., Zhou J.J., Zhu J.H., Gao X.J. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats. J. Control. Release. 2001;71:203–211. doi: 10.1016/S0168-3659(01)00218-8. PubMed DOI

Betancourt T., Byrne J.D., Sunaryo N., Crowder S.W., Kadapakkam M., Patel S., Casciato S., Brannon-Peppas L. PEGylation strategies for active targeting of PLA/PLGA nanoparticles. J. Biomed. Mater. Res. A. 2009;91:263–276. doi: 10.1002/jbm.a.32247. PubMed DOI

Ngaboni Okassa L., Marchais H., Douziech-Eyrolles L., Cohen-Jonathan S., Souce M., Dubois P., Chourpa I. Development and characterization of sub-micron poly(D,L-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles. Int. J. Pharm. 2005;302:187–196. doi: 10.1016/j.ijpharm.2005.06.024. PubMed DOI

Saez V., Cerruti R., Ramón J.A., Santos E.R.F., Silva D.Z., Pinto J.C., Souza F.G. Quantification of Oxaliplatin Encapsulated into PLGA Microspheres by TGA. Macromol. Symp. 2016;368:116–121. doi: 10.1002/masy.201500181. DOI

Yoo J., Won Y.Y. Phenomenology of the Initial Burst Release of Drugs from PLGA Microparticles. ACS Biomater. Sci. Eng. 2020;6:6053–6062. doi: 10.1021/acsbiomaterials.0c01228. PubMed DOI

Avgoustakis K. PLGA–mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control. Release. 2002;79:123–135. doi: 10.1016/S0168-3659(01)00530-2. PubMed DOI

Uhlen M., Zhang C., Lee S., Sjöstedt E., Fagerberg L., Bidkhori G., Benfeitas R., Arif M., Liu Z., Edfors F., et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507. doi: 10.1126/science.aan2507. PubMed DOI

Grothey A., Goldberg R.M. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin. Pharmacother. 2004;5:2159–2170. doi: 10.1517/14656566.5.10.2159. PubMed DOI

Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 2007;63:12–31. doi: 10.1016/j.critrevonc.2007.02.001. PubMed DOI

Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute’s anticancer drug screen panel. Biochem. Pharmacol. 1996;52:1855–1865. doi: 10.1016/S0006-2952(97)81490-6. PubMed DOI

Raymond E., Faivre S., Woynarowski J.M., Chaney S.G. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin. Oncol. 1998;25:4–12. PubMed

Graham J., Mushin M., Kirkpatrick P. Oxaliplatin. Nat. Rev. Drug Discov. 2004;3:11–12. doi: 10.1038/nrd1287. PubMed DOI

de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000;18:2938–2947. doi: 10.1200/JCO.2000.18.16.2938. PubMed DOI

Tummala S., Gowthamarajan K., Satish Kumar M.N., Wadhwani A. Oxaliplatin immuno hybrid nanoparticles for active targeting: An approach for enhanced apoptotic activity and drug delivery to colorectal tumors. Drug Deliv. 2016;23:1773–1787. doi: 10.3109/10717544.2015.1084400. PubMed DOI

Handali S., Ramezani Z., Moghimipour E., Rezaei M., Dorkoosh F.A. A novel method for the simultaneous determination of 5-fluorouracil and oxaliplatin in new biodegradable PHBV/PLGA nanoparticles. J. Iran. Chem. Soc. 2018;16:609–615. doi: 10.1007/s13738-018-1538-1. DOI

Handali S., Moghimipour E., Rezaei M., Saremy S., Dorkoosh F.A. Co-delivery of 5-fluorouracil and oxaliplatin in novel poly(3-hydroxybutyrate-co-3-hydroxyvalerate acid)/poly(lactic-co-glycolic acid) nanoparticles for colon cancer therapy. Int. J. Biol. Macromol. 2019;124:1299–1311. doi: 10.1016/j.ijbiomac.2018.09.119. PubMed DOI

Rezvantalab S., Drude N.I., Moraveji M.K., Guvener N., Koons E.K., Shi Y., Lammers T., Kiessling F. PLGA-Based Nanoparticles in Cancer Treatment. Front. Pharmacol. 2018;9:1260. doi: 10.3389/fphar.2018.01260. PubMed DOI PMC

Mahmoudi M., Sant S., Wang B., Laurent S., Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. Adv. Drug Del. Rev. 2011;63:24–46. doi: 10.1016/j.addr.2010.05.006. PubMed DOI

Fernandez-Alvarez F., Caro C., Garcia-Garcia G., Garcia-Martin M.L., Arias J.L. Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer. J. Mater. Chem. B. 2021;9:4963–4980. doi: 10.1039/D1TB00354B. PubMed DOI

Eynali S., Khoei S., Khoee S., Esmaelbeygi E. Evaluation of the cytotoxic effects of hyperthermia and 5-fluorouracil-loaded magnetic nanoparticles on human colon cancer cell line HT-29. Int. J. Hyperth. 2017;33:327–335. doi: 10.1080/02656736.2016.1243260. PubMed DOI

Costa Lima S.A., Gaspar A., Reis S., Duraes L. Multifunctional nanospheres for co-delivery of methotrexate and mild hyperthermia to colon cancer cells. Mater. Sci. Eng. C. 2017;75:1420–1426. doi: 10.1016/j.msec.2017.03.049. PubMed DOI

Mishra P., Nayak B., Dey R.K. PEGylation in anti-cancer therapy: An overview. Asian J. Pharm. Health Sci. 2016;11:337–348. doi: 10.1016/j.ajps.2015.08.011. DOI

Babos G., Biro E., Meiczinger M., Feczko T. Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles. Polymers. 2018;10:895. doi: 10.3390/polym10080895. PubMed DOI PMC

Kim W.T., Ryu C.J. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017;50:285–298. doi: 10.5483/BMBRep.2017.50.6.039. PubMed DOI PMC